Shanghai‑based D3 Bio closed a $108 million Series B to bankroll a planned global Phase III program for its oral KRAS G12C inhibitor, elisrasib (D3S‑001). The financing positions the company to advance registrational studies and expands the wave of competitors targeting KRAS driver mutations. Investors cited the clinical momentum behind KRAS inhibitors and D3 Bio’s preclinical package as reasons for backing the program. The raise mirrors broader industry appetite for next‑generation KRAS agents and signals continued investor confidence in oncology small‑molecule successors to seminal Amgen/Sotorasib programs. Clarification: KRAS G12C is a common oncogenic mutation in lung and certain other cancers; inhibitors targeting the mutation have become a major oncology focus since the first approvals in this class.